ABUS MEXC RealStocks
Own real ABUS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:24:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Arbutus Biopharma Corporation (ABUS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.12, with a market capitalization of $620.84M and a P/E ratio of 2.82. Over the past 52 weeks, its price has ranged from $3.50 to $5.45. This page covers its latest market performance, valuation, price trends and company information.
$620.84M | |
$4.05 | |
$4.21 | |
$4.03 | |
$4.05 | |
2.56M | |
5.26M | |
2.82 | |
$5.45 | |
$3.50 | |
-- | |
2026-09-30 |
Arbutus Biopharma Corporation (ABUS) last closed at $4.12 as of 2026-11-19 00:31:00, up 1.73% ($0.07) from the previous close of $4.05.
During the latest regular trading session, ABUS traded between $4.03 and $4.21, with a volume of 2.56M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Arbutus Biopharma Corporation (ABUS) moved from $3.82 to $4.12, representing a gain of 7.72% ($0.30).
The stock traded between $3.65 and $4.21 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.89 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31.5%
ABUS is currently trading at $4.12, placing it 31.5% of the way from its 52-week low of $3.50 to its 52-week high of $5.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 19 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arbutus Biopharma Corporation (ABUS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ABUS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ABUS shares and USD.
ABUS Shares to USD
1.00 ABUS shares = 4.115 USD
Calculations are estimates based on the latest available price and are for reference only.